High-Density Lipoprotein may Help Treat Sepsis Patients
Sepsis is a very serious systemic inflammatory disease caused by infection, with few treatment methods and a high mortality rate;Recently, A research report was published in the international journal Science Signaling entitled "Replenishing HDL with Synthetic HDL has multiple protective Effects against Sepsis in Mice." Scientists from the University of Kentucky and other institutions have found that supplementing a community with high-density lipoprotein (HDL) may be an effective treatment for sepsis, Here, the researchers found that a synthetic form of HDL may provide protection against sepsis in mice.
Sepsis is a life-threatening disease. When the infection induces a chain reaction in the body, it will endanger the life of the patient. If the patient with sepsis is not treated in time, it will lead to tissue damage, organ failure and death of the patient. Data from the US CDC shows that about 270,000 Americans die each year due to sepsis, and one-third of patients who die in hospitals have sepsis.
HDL cholesterol is a type of good cholesterol because it helps the body remove other forms of cholesterol from the blood, and high levels of HDL are also associated with a reduced risk of heart disease and stroke in the body, and, according to data in the study, the prognosis for patients with sepsis Often better. In this study, the researchers found that compared with non-septic patients, patients with sepsis tend to have lower levels of HDL cholesterol. In addition, lower levels of HDL are also closely associated with poor prognosis in patients with sepsis.
Combined with the researchers' previous studies in HDL-deficient mice, these findings suggest that reduced HDL levels may be a risk factor for the development of sepsis, and that increasing HDL levels may provide a viable therapeutic strategy to combat sepsis . To test this hypothesis, the researchers examined mice with sepsis using an integrated HDL therapy called ETC-642. The treated mice had improved survival and were protected against sepsis, including improved kidney function and reduced levels of inflammation.
These data suggest that HDL therapy may be an effective treatment for patients with sepsis, and that ETC-642 provides an opportunity for rapid translation into clinical trials; Researchers have previously used ETC-642 to treat cardiovascular disease, and in multiple clinical trials, it has also been shown to be effective in increasing HDL levels in patients, although more research is needed at a later stage, ETC-642's established safety profile in clinical manufacturing and human trials may make it an ideal candidate to advance and test its protective ability in sepsis patients.
Taken together, the results of this study suggest that synthetic HDL may warrant further investigation to elucidate its potential to help treat patients with sepsis.
At present, Wuxi Donglin Sci & Tech Development Co.,Ltd. has developed Elisa products related to HDL, If you want to know information about Elisa kits, you can directly visit the website:
http://www.dldevelop.com/Research-reagent/dl-hdl-hu.html
http://www.dldevelop.com/Research-reagent/dl-hdl-mu.html
http://www.dldevelop.com/Research-reagent/dl-hdl-ra.html
Sepsis is a life-threatening disease. When the infection induces a chain reaction in the body, it will endanger the life of the patient. If the patient with sepsis is not treated in time, it will lead to tissue damage, organ failure and death of the patient. Data from the US CDC shows that about 270,000 Americans die each year due to sepsis, and one-third of patients who die in hospitals have sepsis.
HDL cholesterol is a type of good cholesterol because it helps the body remove other forms of cholesterol from the blood, and high levels of HDL are also associated with a reduced risk of heart disease and stroke in the body, and, according to data in the study, the prognosis for patients with sepsis Often better. In this study, the researchers found that compared with non-septic patients, patients with sepsis tend to have lower levels of HDL cholesterol. In addition, lower levels of HDL are also closely associated with poor prognosis in patients with sepsis.
Combined with the researchers' previous studies in HDL-deficient mice, these findings suggest that reduced HDL levels may be a risk factor for the development of sepsis, and that increasing HDL levels may provide a viable therapeutic strategy to combat sepsis . To test this hypothesis, the researchers examined mice with sepsis using an integrated HDL therapy called ETC-642. The treated mice had improved survival and were protected against sepsis, including improved kidney function and reduced levels of inflammation.
These data suggest that HDL therapy may be an effective treatment for patients with sepsis, and that ETC-642 provides an opportunity for rapid translation into clinical trials; Researchers have previously used ETC-642 to treat cardiovascular disease, and in multiple clinical trials, it has also been shown to be effective in increasing HDL levels in patients, although more research is needed at a later stage, ETC-642's established safety profile in clinical manufacturing and human trials may make it an ideal candidate to advance and test its protective ability in sepsis patients.
Taken together, the results of this study suggest that synthetic HDL may warrant further investigation to elucidate its potential to help treat patients with sepsis.
At present, Wuxi Donglin Sci & Tech Development Co.,Ltd. has developed Elisa products related to HDL, If you want to know information about Elisa kits, you can directly visit the website:
http://www.dldevelop.com/Research-reagent/dl-hdl-hu.html
http://www.dldevelop.com/Research-reagent/dl-hdl-mu.html
http://www.dldevelop.com/Research-reagent/dl-hdl-ra.html
